CoChat

Pramipexole, a Dopamine Agonist, in Major Depression: Antidepressant Effects and Tolerability in an Open-Label Study with Multiple Doses

Szegedi, Armin, Hillert, Andreas, Wetzel, Hermann, Klieser, Eckard, Gaebel, Wolfgang, Benkert, Otto · 1997 · Clinical Neuropharmacology
Cited by 47

The DOI matches its Crossref record.

Abstract

Summary: The safety, tolerability, and the antidepressant effects of pramipexole, a dopaminergic agonist, were assessed in 26 patients hospitalized for major depression. Total daily doses ranged from 1.75 to 9.0 mg using a 14-day dose escalation phase to reach the target or highest attainable dose, which was then administered unchanged for an additional 14 days. The study was terminated at the 6.25-mg dose level because nausea, restlessness, headache, and insomnia became dose-limiting. No clinically important laboratory, electrocardiographic, or vital sign abnormalities were noted. Ninety-six percent of the patients (25/26) were markedly or severely ill by the Clinical Global Impression severity scale at the start of the study, whereas only 27% (7/26) remained in this category at the final visit. Pramipexole administration resulted in consistent reductions in clinical depression. Scores on three major rating scales showed reductions of ≥35% in 13, 12, and 10 of the 26 patients, respectively. A more marked improvement of at least 50% was also noted in a substantial number of patients (MADRS 9/26, BRMES 7/26, and HAMD-17 6/26). This escalating dose-tolerance study with preliminary efficacy data demonstrated sufficient safety and antidepressant properties of pramipexole in severely depressed patients to justify a larger doubleblind, placebo-controlled trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00002826-199720001-00006

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 47

Metadata

Authors
Szegedi, A., Hillert, A., Wetzel, H., Klieser, E., Gaebel, W., & Benkert, O.
Venue
Clinical Neuropharmacology
Published
1997
Volume
20
Pages
S36-S45
ISSN
0362-5664 (ISSN-L)
OpenAlex
W2330280326
Cited by
47
References
0
FWCI
2.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pramipexole, a Dopamine Agonist, in Major Depression: Antidepressant Effects and Tolerability in an Open-Label Study with Multiple Doses. https://app.cochat.ai/papers/10.1097/00002826-199720001-00006
The paper
Szegedi, A., Hillert, A., Wetzel, H., Klieser, E., Gaebel, W., & Benkert, O. (1997). Pramipexole, a Dopamine Agonist, in Major Depression: Antidepressant Effects and Tolerability in an Open-Label Study with Multiple Doses. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-199720001-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.